The Alliance Executive Committee is chaired by the Group Chair and includes the Group Vice Chair, Program Directors, and eight representatives elected from the Board of Directors, including four Principal Investigators from academic member institutions and four Principal Investigators from community member institutions. The Executive Committee sets the scientific agenda of the Group by approving protocols at the concept stage. In addition, the Executive Committee approves the appointment of the Chairs of the Disease and Modality committees and is responsible for the management of Group affairs.

Portrait photo of Evanthia Galanis

Group Chair

Evanthia Galanis, MD, DSc

Professor of Oncology, the Sandra J. Schulze Professor of Novel Therapeutics, and the Executive Dean for Development at Mayo Clinic

Dr. Galanis is responsible for overall scientific, operational, and administrative leadership of the organization. She is an internationally recognized expert in neuro-oncology and a clinician-investigator with a long-standing interest in developing novel therapeutic approaches for cancer.


Portrait photo of David Kozono

Group VIce Chair

David E. Kozono, MD, PhD

Associate Professor of Radiation Oncology at Harvard Medical School and Director of Thoracic Radiation Oncology at Dana-Farber/Brigham and Women’s Cancer Center

Dr. Kozono specializes in the treatment of thoracic malignancies, including lung cancer, and he is committed to bringing scientific discoveries into the design and conduct of innovative clinical trials with robust translational medicine objectives.

Program principal investigators

Program principal investigators for the direct the scientific, administrative, and operational activities of the group’s five core research programs under the guidance of the Group Chair.

Example DO NOT USE

Central Protocol Operations Program

Olwen Hahn, MD

University of Chicago Medcine

Executive committee representatives

Through regular collaboration, the Executive Committee Representatives evaluates emerging scientific opportunities, establishes research priorities, oversees operational performance, and guides decisions that advance the Alliance’s clinical research network. By bringing together leaders from across the organization, the Executive Committee ensures that scientific innovation, operational excellence, and multidisciplinary collaboration remain central to every Alliance initiative.

Executive Committee

William Irvin Jr., MD

Southeast Clinical Oncology Research Consortium NCORP

Executive Committee

Gregory Masters, MD

Delaware/Christiana Care NCI Community Oncology Research Program

Executive Committee

Matthew Milowsky, MD

UNC Lineberger Comprehensive Cancer Center

Executive Committee

Ronica Nanda, MD

Morton Plant Hospital

Executive Committee

Claire Verschraegen, MD, MS

Ohio State University Comprehensive Cancer Center LAPS